Published in Br J Clin Pharmacol on September 01, 2010
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol (2010) 1.01
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol (2014) 0.80
The journal's policy on cost-effectiveness analyses. N Engl J Med (1994) 5.50
The decade of NICE. Lancet (2009) 4.30
Value based pricing for NHS drugs: an opportunity not to be missed? BMJ (2008) 3.33
Protecting the medical commons: who is responsible? N Engl J Med (1975) 3.08
Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med (1991) 2.46
Is there a need for an independent centre for pharmacoeconomics in the UK? Pharmacoeconomics (1994) 1.53
Publication bias in health economic studies. Pharmacoeconomics (1997) 1.26
Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing? CNS Drugs (2004) 0.94
Drugs, money and society. Br J Clin Pharmacol (1995) 0.93
Risk sharing and payment by results. Clin Pharmacol Ther (2008) 0.92
NICE vindicated in UK's High Court. Lancet (2007) 0.87
Pharmacoeconomics is coming of age. Clin Pharmacol Ther (2008) 0.80
Pharmacoeconomics: a challenge for clinical pharmacologists. Br J Clin Pharmacol (1995) 0.80
Pharmacoeconomics comes of age? Clin Pharmacol Ther (2008) 0.79
NICE wobbles. J R Soc Med (2009) 0.79